Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 3Thrombocytosis 1Smoldering Multiple Myeloma 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Monoclonal Gammopathy of Undetermined Significance 1Lymphoma, Non-Hodgkin 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Hematologic Neoplasms 1Breast Neoplasms 1Blast Crisis 1Anemia 1

Interventions

Peripheral Blood Stem Cell Transplantation 4Cyclophosphamide 4fludarabine phosphate 3Epoetin Alfa 3Darbepoetin alfa 3Curcumin 3liposomal amphotericin B 2Whole-Body Irradiation 2Tacrolimus 2Mycophenolic Acid 2Morphine 2Methylprednisolone 2Interferon-alpha 2Filgrastim 2Fentanyl 2Cytogenetic Analysis 2Cyclosporine 2Caspofungin 2Carboplatin 2Busulfan 2Bortezomib 2Antilymphocyte Serum 2siltuximab 1sargramostim 1pyroxamide 1piperine 1isatuximab 1ferrous sulfate 1ferric gluconate 1alethine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Monoclonal Gammopathy of Undetermined Significance × Celecoxib × Plasma cell × Clear all
NCT00099047 2016-12-30

Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma

National Cancer Institute (NCI)

Phase 2 Completed
23 enrolled 7 charts
Plasma cell

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡